You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 28, 2024

Bevacizumab - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for bevacizumab
Recent Clinical Trials for bevacizumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Michael DillPhase 2
German Cancer Research CenterPhase 2
Universitätsmedizin MannheimPhase 2

See all bevacizumab clinical trials

Recent Litigation for bevacizumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
GENENTECH, INC. v. DR. REDDYS LABORATORIES, INC.2023-11-17
Taiho Pharmaceutical Co., Ltd. v. Eugia Pharma Specialities Ltd.2023-10-20
Genentech, Inc. v. Biogen MA Inc.2023-07-13

See all bevacizumab litigation

PTAB Litigation
PetitionerDate
Illumina, Inc. et al.2021-07-20
Laboratory Corporation of America Holdings et al.2021-05-28
Quest Diagnostics Incorporated2021-04-15

See all bevacizumab litigation

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for bevacizumab Derived from Brand-Side Litigation

These patents were obtained from brand-side disclosures in response to biosimilar applications
Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Patent Expiration
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Sign Up 2034-03-14
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Sign Up 2030-08-06
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Sign Up 2034-03-14
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Sign Up 2025-03-08
Genentech, Inc. AVASTIN bevacizumab Injection 125085 02/26/2004 ⤷  Sign Up 2031-08-18
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Patent Expiration

2) High Certainty: US Patents for bevacizumab Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Genentech, Inc. AVASTIN bevacizumab Injection 125085 ⤷  Sign Up 2014-01-25 Company disclosures
Genentech, Inc. AVASTIN bevacizumab Injection 125085 ⤷  Sign Up 2020-08-05 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for bevacizumab Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for bevacizumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122006000043 Germany ⤷  Sign Up PRODUCT NAME: NATALIZUMAB; NAT. REGISTRATION NO/DATE: EU /1/06/346/001 20060627; FIRST REGISTRATION: EU EU/1/06/346/001 20060627
300238 Netherlands ⤷  Sign Up PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060630
91271 Luxembourg ⤷  Sign Up PRODUCT NAME: NATALIZUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES ( TYSABRI ); AUTHORISATION NUMBER AND DATE: EU/1/06/346/001
C300238 Netherlands ⤷  Sign Up PRODUCT NAME: NATALIZUMAB; REGISTRATION NO/DATE: EU/1/06/346/001 20060627
SPC/GB06/025 United Kingdom ⤷  Sign Up PRODUCT NAME: NATALIZUMAB, ANTI -4 INTEGRIN HUMANIZED MONOCLONAL ANTIBODY; REGISTERED: UK EU/1/06/346/001 20060627
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.